Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting the ANGPT-TIE2 pathway in malignancy.

Literature DB >> 20651738

Targeting the ANGPT-TIE2 pathway in malignancy.

Hanhua Huang¹, Abhijit Bhat, Gary Woodnutt, Rodney Lappe.

Abstract

Angiopoietins (ANGPTs) are ligands of the endothelial cell receptor TIE2 and have crucial roles in the tumour angiogenic switch. Increased expression of ANGPT2 relative to ANGPT1 in tumours correlates with poor prognosis. The biological effects of the ANGPT-TIE system are context dependent, which brings into question what the best strategy is to target this pathway. This Review presents an encompassing picture of what we know about this important axis in tumour biology. The various options for therapeutic intervention are discussed to identify the best path forwards.

Entities: Disease Gene

Mesh：

Substances：

Year: 2010 PMID： 20651738 DOI： 10.1038/nrc2894

Source DB: PubMed Journal: Nat Rev Cancer ISSN： 1474-175X Impact factor: 60.716

155 in total

1. Jagged gives endothelial tip cells an edge.

Authors: Steven Suchting; Anne Eichmann
Journal: Cell Date: 2009-06-12 Impact factor: 41.582

2. Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells.

Authors: Injune Kim; Jong-Lark Oh; Young Shin Ryu; June-No So; William C Sessa; Kenneth Walsh; Gou Young Koh
Journal: FASEB J Date: 2001-11-29 Impact factor: 5.191

3. Molecular cloning and characterization of a novel receptor protein tyrosine kinase from human placenta.

Authors: S F Ziegler; T A Bird; J A Schneringer; K A Schooley; P R Baum
Journal: Oncogene Date: 1993-03 Impact factor: 9.867

Review 4. Myeloid cells functioning in tumor vascularization as a novel therapeutic target.

Authors: Karen McLean; Ronald J Buckanovich
Journal: Transl Res Date: 2007-12-26 Impact factor: 7.012

5. Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice.

Authors: Michael Dellinger; Robert Hunter; Michael Bernas; Nicholas Gale; George Yancopoulos; Robert Erickson; Marlys Witte
Journal: Dev Biol Date: 2008-04-27 Impact factor: 3.582

6. Angiopoietin-2 exocytosis is stimulated by sphingosine-1-phosphate in human blood and lymphatic endothelial cells.

Authors: Cholsoon Jang; Young Jun Koh; Nam Kyu Lim; Hyun Jung Kang; Duk Hoon Kim; Sung Kwang Park; Gyun Min Lee; Choon Ju Jeon; Gou Young Koh
Journal: Arterioscler Thromb Vasc Biol Date: 2008-12-26 Impact factor: 8.311

7. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors: John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal: Cancer Cell Date: 2009-03-03 Impact factor: 31.743

8. A designed angiopoietin-2 variant, pentameric COMP-Ang2, strongly activates Tie2 receptor and stimulates angiogenesis.

Authors: Hak-Zoo Kim; Keehoon Jung; Ho Min Kim; Yifan Cheng; Gou Young Koh
Journal: Biochim Biophys Acta Date: 2009-02-10

9. Regulated proteolytic processing of Tie1 modulates ligand responsiveness of the receptor-tyrosine kinase Tie2.

Authors: Marie B Marron; Harprit Singh; Tariq A Tahir; Jais Kavumkal; Hak-Zoo Kim; Gou Young Koh; Nicholas P J Brindle
Journal: J Biol Chem Date: 2007-08-29 Impact factor: 5.157

10. Angiopoietin-2: modulator of vascular permeability in acute lung injury?

Authors: Tomoki Hashimoto; Jean-Francois Pittet
Journal: PLoS Med Date: 2006-02-07 Impact factor: 11.069

179 in total

Review 1. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Authors: Shom Goel; Andus Hon-Kit Wong; Rakesh K Jain
Journal: Cold Spring Harb Perspect Med Date: 2012-03 Impact factor: 6.915

2. Tie1 deficiency induces endothelial-mesenchymal transition.

Authors: Julie Garcia; Maria José Sandi; Pierre Cordelier; Bernard Binétruy; Jacques Pouysségur; Juan Lucio Iovanna; Roselyne Tournaire
Journal: EMBO Rep Date: 2012-05-01 Impact factor: 8.807

3. ΔNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma.

Authors: Maren Cam; Manish Charan; Alessandra M Welker; Piyush Dravid; Adam W Studebaker; Jeffrey R Leonard; Christopher R Pierson; Ichiro Nakano; Christine E Beattie; Eugene I Hwang; Madhuri Kambhampati; Javad Nazarian; Jonathan L Finlay; Hakan Cam
Journal: Neuro Oncol Date: 2020-03-05 Impact factor: 12.300

4. Understanding and targeting resistance to anti-angiogenic therapies.

Authors: Jeffrey M Clarke; Herbert I Hurwitz
Journal: J Gastrointest Oncol Date: 2013-09

5. Photoacoustic Tomography Detects Early Vessel Regression and Normalization During Ovarian Tumor Response to the Antiangiogenic Therapy Trebananib.

Authors: Sarah E Bohndiek; Laura S Sasportas; Steven Machtaler; Jesse V Jokerst; Sharon Hori; Sanjiv S Gambhir
Journal: J Nucl Med Date: 2015-08-27 Impact factor: 10.057

6. High Expression of Angiopoietin-1 is Associated with Lymph Node Metastasis and Invasiveness of Papillary Thyroid Carcinoma.

Authors: Yea Eun Kang; Koon Soon Kim; Sung Jae Park; Seung-Nam Jung; Jae Won Chang; Shinae Yi; Min Gyu Jung; Jin-Man Kim; Bon Seok Koo
Journal: World J Surg Date: 2017-12 Impact factor: 3.352

7. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight.

Authors: James E Dahlman; Carmen Barnes; Omar Khan; Aude Thiriot; Siddharth Jhunjunwala; Taylor E Shaw; Yiping Xing; Hendrik B Sager; Gaurav Sahay; Lauren Speciner; Andrew Bader; Roman L Bogorad; Hao Yin; Tim Racie; Yizhou Dong; Shan Jiang; Danielle Seedorf; Apeksha Dave; Kamaljeet S Sandu; Matthew J Webber; Tatiana Novobrantseva; Vera M Ruda; Abigail K R Lytton-Jean; Christopher G Levins; Brian Kalish; Dayna K Mudge; Mario Perez; Ludmila Abezgauz; Partha Dutta; Lynelle Smith; Klaus Charisse; Mark W Kieran; Kevin Fitzgerald; Matthias Nahrendorf; Dganit Danino; Rubin M Tuder; Ulrich H von Andrian; Akin Akinc; Avi Schroeder; Dipak Panigrahy; Victor Kotelianski; Robert Langer; Daniel G Anderson
Journal: Nat Nanotechnol Date: 2014-05-11 Impact factor: 39.213

8. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.

Authors: Guillermo Garcia-Manero; Hanna J Khoury; Elias Jabbour; Jeffrey Lancet; Shannon L Winski; LouAnn Cable; Selena Rush; Lara Maloney; Grant Hogeland; Mieke Ptaszynski; Monica Cabrero Calvo; Zach Bohannan; Alan List; Hagop Kantarjian; Rami Komrokji
Journal: Clin Cancer Res Date: 2014-12-05 Impact factor: 12.531

9. Tumor-on-a-chip platform to interrogate the role of macrophages in tumor progression.

Authors: Ye Bi; Venktesh S Shirure; Ruiyang Liu; Cassandra Cunningham; Li Ding; J Mark Meacham; S Peter Goedegebuure; Steven C George; Ryan C Fields
Journal: Integr Biol (Camb) Date: 2020-09-30 Impact factor: 2.192

10. Nanomedicines for Endothelial Disorders.

Authors: Bomy Lee Chung; Michael J Toth; Nazila Kamaly; Yoshitaka J Sei; Jacob Becraft; Willem J M Mulder; Zahi A Fayad; Omid C Farokhzad; YongTae Kim; Robert Langer
Journal: Nano Today Date: 2015-12-01 Impact factor: 20.722